Eversept Partners, LP Biocryst Pharmaceuticals Inc Transaction History
Eversept Partners, LP
- $1.32 Billion
- Q2 2024
A detailed history of Eversept Partners, LP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Eversept Partners, LP holds 1,152,573 shares of BCRX stock, worth $9.23 Million. This represents 0.54% of its overall portfolio holdings.
Number of Shares
1,152,573
Previous 1,432,427
19.54%
Holding current value
$9.23 Million
Previous $7.28 Million
2.12%
% of portfolio
0.54%
Previous 0.55%
Shares
33 transactions
Others Institutions Holding BCRX
# of Institutions
257Shares Held
173MCall Options Held
397KPut Options Held
444K-
Black Rock Inc. New York, NY20MShares$160 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.8MShares$150 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.6MShares$101 Million1.06% of portfolio
-
State Street Corp Boston, MA9.35MShares$74.9 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.83MShares$70.7 Million4.25% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.49B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...